Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antianaphylaxis compound containing epinastine hydrochloride

An epinastine hydrochloride and anti-allergic technology, which is applied in the direction of medical preparations containing active ingredients, drug combinations, allergic diseases, etc., can solve the problems of epinastine hydrochloride and steroids that have not been reported, and achieve anti-allergic Significant effect, reduced adverse reactions, and broad application prospects

Active Publication Date: 2010-12-15
GUANGZHOU YIPINHONG PHARMA +5
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there is no report on the antiallergic composition of epinastine hydrochloride and steroids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antianaphylaxis compound containing epinastine hydrochloride
  • Antianaphylaxis compound containing epinastine hydrochloride

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 Ointment preparation

[0022] The components and contents are as follows:

[0023] Epinastine Hydrochloride 0.8g

[0024] Prednisolone 0.8g

[0025] Vaseline 80g

[0026] Liquid paraffin 9g

[0027] Lanolin 8g

[0028] Pure water 1.4g

[0029] According to the above components and contents, add epinastine hydrochloride and prednisolone into pure water to dissolve, add vaseline-liquid paraffin-lanolin ointment base, mix evenly, separate bacteria, and pack separately to obtain the finished product.

Embodiment 2

[0030] Example 2 Capsule preparation

[0031] The components and contents are as follows:

[0032] Epinastine Hydrochloride 0.4g

[0033] Hydrocortisone 2.0g

[0034] Cyclodextrin 5g

[0035] Microcrystalline Cellulose 60g

[0036] Calcium hydrogen phosphate 20g

[0037] Carboxymethyl Starch Sodium 25g

[0038] Stevia 25g

[0039] Magnesium Stearate 5g

[0040] Micronized silica gel 10g

[0041] Starch lactose 100g

[0042] The above-mentioned various raw materials are dried at low temperature, pulverized, passed through a 100-mesh fine sieve, mixed uniformly, made into a powder, and uniformly granulated by a granulator, and filled into a hollow capsule with a capsule filler after sterilization to obtain a capsule. Capsules contain 0.35 g of granules.

Embodiment 3

[0044] 1. Cases

[0045] 34 cases were verified and treated, including 9 males and 25 females, aged 12 to 63 years, with an average of 32.7 years, and the course of disease ranged from 2 to 40 years, with an average of 8.9 years. All patients had typical symptoms of bronchial asthma or allergic rhinitis. During the treatment, all patients were ineffective or unable to tolerate the treatment.

[0046] 2. Method

[0047] Oral capsules, twice a day, four capsules each time, 0.35 grams per capsule, once in the morning and before going to sleep.

[0048] The whole course of treatment for each patient was one and a half months, divided into three observation periods. The first observation period lasts for half a month. During this period, the capsules are taken orally every day according to the doctor’s advice; the second observation period also lasts for half a month, and the capsules are stopped during this period; the third observation period still lasts for half a month Durin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-allergy compound containing epinastine hydrochloride, consisting of the following components by weight portion: epinastine hydrochloride of 1 portion and steroid of 1 to 7. The invention discovers that the epinastine hydrochloride and the steroid can have the coordination function when the epinastine hydrochloride and the steroid are combined to use in certain proportion range, which not only reduces the adverse reaction, but also reduces the dosage with the obvious anti-allergy effect and wide application outlook, thus being good for population.

Description

technical field [0001] The invention relates to the field of antiallergic drugs, in particular to an antiallergic composition containing epinastine hydrochloride. Background technique [0002] Antihistamines are subdivided into H 1 Receptor antagonists (customarily called antihistamines or antiallergic drugs) and H 2 Receptor antagonists, clinically known as H 1 Receptor antagonists are the most widely used. Since the first antihistamine was developed in 1937, there have been more than 50 kinds of H 1 Receptor antagonists for clinical use. [0003] Antihistamines before the 1980s were the first generation of antihistamines, because of their central inhibitory effect and H 1 The two shortcomings of poor receptor selectivity limit its further clinical use; antihistamines after the 1980s are the second generation of antihistamines, which not only have the same curative effect on rhinitis, asthma and other diseases, but also have mild central reaction, h 1 Three significan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/573A61K31/575A61K31/58A61P37/08A61K31/55
Inventor 王勇
Owner GUANGZHOU YIPINHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com